Facts:
This indication alone is worth at least USD $1B in annual revenue to a future buyer.
- Quite incredible tumour regression in Extremedullary AML.
- This from a single dose. The normal dosing is two doses.
- Unmet medical need so very strong potential for fast-tack approval from a pivotal trial.
Huge overhang of potential sellers here, page-20
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.63 |
Change
0.000(0.00%) |
Mkt cap ! $276.9M | |||
| Open | High | Low | Value | Volume |
| $1.64 | $1.64 | $1.62 | $56.91K | 35.04K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 4461 | $1.63 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.66 | 4075 | 1 |
View Market Depth
| Last trade - 16.10pm 11/09/2024 (20 minute delay) ? |
| RAC (ASX) Chart |